Erman Akkus: Future biomarkers will be more than PD-L1 for ICI
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“B-cell infiltration as a biomarker in recurrent/metastatic HNSCC treated by nivolumab
– 60 patients, prospectively, tumor biopsies and blood samples at baseline, post-treatment, and at progression
– High pre-treatment density of stromal (but not in tumor tissue) B-cells -> prolonged PFS (Hazard Ratio: 0.44, p=0.011)
– High pre-treatment plasma cell infiltration -> prolonged PFS (Hazard Ratio: 0.38, p=0.007)
– PD-L1/CD20 double positive patients demonstrated a significant survival advantage compared to double negative tumors: PFS 5.3 months vs 1.9 months (Hazard Ratio, 0.31; p = 0.0087) and OS 17.2 months vs 4.5 months, Hazard Ratio, 0.28; p = 0.0024)
– Stromal enrichment with B-cell-associated genes > association with both response (p=0.027) and disease control (p=0.038) to nivolumab
Future biomarkers will be more than PD-L1 for ICI.”
For details click here.
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023